Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Petry

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 3, 2008
Atazanavir modestly increases plasma levels of raltegravir in healthy subjectsMarian Iwamoto, Larissa A Wenning, Goutam C Mistry, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Journal of Clinical Pharmacology|December 14, 2007
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationMarian Iwamoto, Kelem Kassahun, Matthew D Troyer, et al.
Microbial Pathogenesis|September 3, 2019
Trypanosoma evansi impacts on embryonic neural progenitor cell functionsMateus Fracasso, Micheli M Pillat, Nathieli B Bottari, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirLarissa A Wenning, William D Hanley, Diana M Brainard, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 3, 2008
Atazanavir modestly increases plasma levels of raltegravir in healthy subjectsMarian Iwamoto, Larissa A Wenning, Goutam C Mistry, et al.
Clinical Pharmacology and Therapeutics|August 24, 2007
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjectsM Iwamoto, L A Wenning, A S Petry, et al.
Journal of Clinical Pharmacology|December 14, 2007
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationMarian Iwamoto, Kelem Kassahun, Matthew D Troyer, et al.
Microbial Pathogenesis|September 3, 2019
Trypanosoma evansi impacts on embryonic neural progenitor cell functionsMateus Fracasso, Micheli M Pillat, Nathieli B Bottari, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravirLarissa A Wenning, William D Hanley, Diana M Brainard, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphismsL A Wenning, A S Petry, J T Kost, et al.
Pageof 5